| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | S-3 |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
NEW YORK, November 10, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including... |
| 24 Aug 2026 | 144 |
| 14 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Financial Statements and Exhibits
NEW YORK, August 13, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including f... |
| 29 Jul 2026 | SCHEDULE 13G |
| 08 Jul 2026 |
Form 4: Carter Charles Ross, Chief Financial Officer
Received 50,000 shares as a grant or award |
| 08 Jul 2026 |
Form 3: Carter Charles Ross, Chief Financial Officer
Holds 44,375 shares of Common Stock |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 08 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 5, 2026, Ovid Therapeutics Inc. (the “Company”) and Jeffrey Rona, who served as the Company’s Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary, mutually agreed to Mr. R... |
| 17 Jun 2026 |
Form 4: Greka Anna, Director
Granted 130,000 Stock Option (right to buy) |
| 17 Jun 2026 |
Form 3: Greka Anna, Director
No securities owned |
Loading...